英国上市公司365

Global
关于英国上市公司365

致力于纳米抗体
创新药物研发

关于英国上市公司365
科研论文
截止现在，英国上市公司365生物研发团队在具有重要影响力的期刊上发表研究论文多篇。
2024-12-03
Efficient development of nanobody-based affinity chromatography for AAV8 purification.
发表于:Protein Expression and Purification
查看更多内容
2024-10-30
Ce-MOF@Au-Based Electrochemical Immunosensor for Apolipoprotein A1 Detection Using Nanobody Technology.
发表于:ACS Applied Materials & Interfaces
查看更多内容
2024-06-11
A novel inhalable nanobody targeting IL-4Rα for the treatment of asthma.
发表于:J Allergy Clin Immunol.
查看更多内容
2024-06-10
Nanobody-Based Microfluidic Immunosensor Chip Using Tetraphenylethylene-Derived Covalent Organic Frameworks as Aggregation-Induced Electrochemiluminescence Emitters for the Detection of Thymic Stromal Lymphopoietin.
发表于:Analytical Chemistry
查看更多内容
2024-05-16
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.
发表于:Journal of Nanobiotechnology.
查看更多内容
2024-02-16
High performance production process development and scale-up of ananti-TSLP nanobody
发表于:Protein expression and purification, 218, 106441.
查看更多内容
总计 24 1234